Impact of Rosuvastatin in Contrast-Induced Acute Kidney Injury in the Elderly: Post Hoc Analysis of the PRATO-ACS Trial

Conclusion:
Patients ≥75 years with ACS had a higher risk of developing CI-AKI. Early high-dose rosuvastatin is efficacious in reducing kidney injury in all patients, especially those with the highest baseline hs-CRP values.

Source: Journal of Cardiovascular Pharmacology and Therapeutics - February 24, 2016 Category: Cardiology Authors: Tropeano, F., Leoncini, M., Toso, A., Maioli, M., Dabizzi, L., Biagini, D., Villani, S., Bellandi, F. Tags: Clinical Studies Source Type: research